News for Targovax ASA (TRVXO.OL)

Revolution is pioneering a unique precision-based approach to developing oncology drugs that target the RAS pathway. Read why I'm neutral on RVMD stock.

Feb 16, 2023 / 09:00AM GMTErik Digman Wiklund - Targovax ASA - CEO Welcome to Targovax and the presentation of our Q4 results for 2022. My name is Erik Digman W

Nov 03, 2022 / 09:00AM GMTErik Digman Wiklund - Targovax ASA - CEO Welcome to Targovax and the presentation of our third quarter results. My name is Erik Digman

May 12, 2022 / 08:00AM GMTErik Digman Wiklund - Targovax ASA - CEO Welcome to Targovax and our first quarter update. My name is Erik Digman Wiklund and I am the

Feb 17, 2022 / 09:00AM GMTPresentationFeb 17, 2022 / 09:00AM GMT =====================Corporate Participants===================== * Erik Digman Wiklund

Aug 18, 2021 / 08:00AM GMTÃystein Soug - Targovax ASA - CEO Ladies and gentlemen, welcome to Targovax in our second quarter presentation. I'm the CEO. My name

Feb 18, 2021 / 01:30PM GMTÃystein Soug - Targovax ASA - CEO Ladies and gentlemen, please let me welcome you to our Capital Markets Day, our key opinion leader

Dec 02, 2020 / 09:00AM GMTÃystein Soug - And welcome to this ad hoc webcast and presentation. My name is Ãystein Soug, and I am the CEO of Targovax. So most

Jun 25, 2020 / 03:30PM GMTNicholas Colangelo;SOLEBURY TROUT LLC;Analyst - Thank you for attending the European Biotech Investor Day hosted by Solebury Trout, G

May 07, 2020 / 08:00AM GMTTorbjørn Furuseth - Targovax ASA - CFO Good morning, everyone, and welcome to Targovax' First Quarter Virtual Quarterly Presentatio

The prevalence of mesothelioma has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence...

/PRNewswire/ -- DelveInsight's 'Pancreatic Cancer Pipeline Insight – 2022' report provides comprehensive global coverage of available, marketed, and pipeline...

OSLO, Norway, March 4, 2021 /PRNewswire/ -- Oslo, 4 March 2021: Reference is made to the stock exchange announcement by Targovax ASA (OSE: TRVX) (...

OSLO, Norway, Feb. 23, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to tar...

OSLO, Feb. 18, 2021 /PRNewswire/ -- Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat so...

/PRNewswire/ -- Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will host a virtual...

OSLO, Feb. 18, 2021 /PRNewswire/ -- Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat so...

/PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immune-oncology company developing immune activators to target hard-to-treat solid tumors, today...

- The parties will explore the feasibility and effect of combining their respective oncolytic virus and receptor tyrosine kinase (RTK) inhibitor t...